金河生物(002688) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 519,765,405.51, representing a 12.46% increase compared to CNY 462,170,158.21 in the same period last year[4] - Net profit attributable to shareholders decreased by 54.61% to CNY 31,771,635.03 from CNY 70,001,205.48 year-on-year[4] - The total profit for the period decreased by 44.52%, amounting to CNY 46,800,000.00, primarily due to increased raw material and energy costs[10] - The company reported a significant decrease in net profit margin, with the basic earnings per share dropping by 63.64% to CNY 0.04 from CNY 0.11[4] - Basic earnings per share decreased by CNY 0.07, a decline of 63.64%, mainly due to reduced net profit attributable to the parent company and an increase in total share capital from a private placement[14] - Net profit for Q1 2022 was CNY 43,496,662.89, a decrease of 44.4% from CNY 78,069,980.89 in Q1 2021[31] - The company reported a decrease in comprehensive income to CNY 41,952,788.32 from CNY 80,648,225.78 in the previous year, indicating a decline of 48.0%[31] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching CNY 36,811,868.07, a 245.37% increase from a negative CNY 25,322,456.62 in the previous year[4] - The net cash flow from operating activities increased by CNY 62,134,324.69, an increase of 245.37%, driven by increased operating revenue and cash collection[15] - Cash and cash equivalents net increase decreased by CNY 94,125,422.80, a decline of 110.14%, mainly due to the completion of a private placement in July of the previous year[17] - The cash inflow from financing activities decreased by CNY 219,149,945.66, a decline of 31.81%, due to reduced borrowing from financial institutions[16] - The net cash flow from financing activities decreased by CNY 156,825,905.28, a decline of 88.11%, reflecting a strategic adjustment in financing to reduce financial costs[16] - The company experienced a net decrease in cash and cash equivalents of 8,666,247.65, contrasting with an increase of 85,459,175.15 in the prior year[35] - The cash inflow from financing activities totaled 469,706,529.34, down from 688,856,475.00 year-over-year[35] Assets and Liabilities - The company's total assets increased by 3.45% to CNY 4,204,623,492.54 compared to CNY 4,064,525,859.70 at the end of the previous year[4] - The total liabilities increased to CNY 1,435,183,626.22 from CNY 1,368,031,689.97, marking a rise of 4.9%[30] - The total equity attributable to shareholders of the parent company was CNY 2,469,375,524.97, up from CNY 2,438,211,286.94, reflecting a growth of 1.3%[30] - The company's cash and cash equivalents amounted to RMB 576,243,020.41, up from RMB 517,659,268.06, indicating an increase of about 11.3%[26] - Accounts receivable decreased to RMB 335,716,921.62 from RMB 352,760,335.51, representing a decline of approximately 4.8%[26] - Inventory levels rose to RMB 606,560,301.70 from RMB 577,196,806.30, marking an increase of around 5.1%[27] - Short-term borrowings increased to RMB 908,849,684.56 from RMB 833,899,423.85, which is an increase of about 9.0%[27] Operational Efficiency and Cost Management - The gross profit margin was impacted by rising costs, with operating costs increasing by 32.43% to CNY 88,591,761.06 compared to the same period last year[9] - Financial expenses rose by 33.23% to CNY 17,020,000.00, primarily due to exchange losses from currency fluctuations[9] - Other income increased by 51.26% to CNY 5,973,000.00, mainly due to higher government subsidies received during the period[9] - The company plans to focus on improving operational efficiency and managing costs in response to the challenging market conditions[11] - Research and development expenses for Q1 2022 were CNY 19,280,982.50, an increase of 11.0% from CNY 17,370,744.69 in Q1 2021[30] Projects and Future Plans - The company is constructing a new project with an annual production capacity of 52,000 tons of veterinary-grade high-efficiency gold streptomycin and 1,000 tons of hydrochloride gold streptomycin, expected to complete civil engineering by the end of 2022[23] - The company has initiated the "Hydrochloride Doxycycline Project" in collaboration with related parties, with construction expected to be completed and trial production by the end of 2022[24]